Understand the source comparison
Ligament Repair Peptides 2026 Update: Comparison Table
BPC-157 VEGF upregulation, angiogenesis, nitric oxide pathway activation 250–500mcg daily subcutaneous, localized near injury site 28 days refrigerated in bacteriostatic water; <72 hours in sterile water Days 14–56 (proliferative and early remodelling phases)
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, angiogenesis, nitric oxide pathway activation
- 250–500mcg daily subcutaneous, localized near injury site
- 28 days refrigerated in bacteriostatic water; <72 hours in sterile water
- Days 14–56 (proliferative and early remodelling phases)
- Best evidence for tendon-to-bone healing; requires daily administration for consistent fibroblast stimulation
- TB-500 (Thymosin Beta-4)
- Actin upregulation, cell migration, anti-inflammatory via downregulation of pro-inflammatory cytokines
- 750mcg twice weekly subcutaneous, first 8 weeks; then 750mcg weekly weeks 9–12
- 28 days refrigerated in bacteriostatic water
- Days 0–28 (inflammatory and early proliferative phases)
- Superior for acute injury response and cell recruitment; synergistic when sequenced before BPC-157
- Cartalax Peptide
- Cartilage matrix protein synthesis, chondrocyte proliferation
- Research dosing varies by model; consult supplier documentation
- Compound-specific. Verify with supplier
- Adjunct to ligament repair during remodelling phase (cartilage interface support)
- Useful in multi-tissue injuries where cartilage is also compromised; limited direct ligament repair evidence